The company said in a June statement that drugs like Remicade, used to treat conditions like ulcerative colitis, can cost roughly $30,000 annually.
“While life-saving and life-changing, this presents a significant challenge for health plans and can be financially devastating for patients,” the statement said.
Biosimilars are clinically equivalent alternatives to biologics like Remicade, and can reduce drug spending by up to $375 billion over the next decade, according to the statement.
At the Becker's 5th Annual Fall Payer Issues Roundtable, taking place November 2–3 in Chicago, payer executives and healthcare leaders will come together to discuss value-based care, regulatory changes, cost management strategies and innovations shaping the future of payer-provider collaboration. Apply for complimentary registration now.
